This company listing is no longer active
EBAC Stock Overview
European Biotech Acquisition Corp. does not have significant operations.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
European Biotech Acquisition Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.19 |
52 Week High | US$14.10 |
52 Week Low | US$9.28 |
Beta | 0 |
1 Month Change | 10.19% |
3 Month Change | 11.79% |
1 Year Change | 14.89% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | n/a |
Recent News & Updates
Recent updates
Shareholder Returns
EBAC | US Capital Markets | US Market | |
---|---|---|---|
7D | 4.1% | 2.4% | 2.1% |
1Y | 14.9% | 34.5% | 30.4% |
Return vs Industry: EBAC exceeded the US Capital Markets industry which returned -8.1% over the past year.
Return vs Market: EBAC exceeded the US Market which returned -10.9% over the past year.
Price Volatility
EBAC volatility | |
---|---|
EBAC Average Weekly Movement | 7.6% |
Capital Markets Industry Average Movement | 3.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EBAC has not had significant price volatility in the past 3 months.
Volatility Over Time: EBAC's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2021 | n/a | Eduardo Bravo de Araoz | https://www.lspvc.com/ebac |
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on business in the life sciences industry in Europe.
European Biotech Acquisition Corp. Fundamentals Summary
EBAC fundamental statistics | |
---|---|
Market cap | US$183.50m |
Earnings (TTM) | US$860.48k |
Revenue (TTM) | n/a |
213.3x
P/E Ratio0.0x
P/S RatioIs EBAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EBAC income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | -US$860.48k |
Earnings | US$860.48k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.052 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did EBAC perform over the long term?
See historical performance and comparison